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Abstract
Background: Smoking status, alcohol consumption and HPV infection (acquired through sexual activity) are the
predominant risk factors for oropharyngeal cancer and are thought to alter the prognosis of the disease. Here, we
conducted single-site and differentially methylated region (DMR) epigenome-wide association studies (EWAS) of
these factors, in addition to ∼ 3-year survival, using Illumina Methylation EPIC DNA methylation profiles from whole
blood in 409 individuals as part of the Head and Neck 5000 (HN5000) study. Overlapping sites between each factor
and survival were then assessed using two-step Mendelian randomization to assess whether methylation at these
positions causally affected survival.
Results: Using the MethylationEPIC array in an OPC dataset, we found novel CpG associations with smoking,
alcohol consumption and ~ 3-year survival. We found no CpG associations below our multiple testing threshold
associated with HPV16 E6 serological response (used as a proxy for HPV infection). CpG site associations below our
multiple-testing threshold (PBonferroni < 0.05) for both a prognostic factor and survival were observed at four gene
regions: SPEG (smoking), GFI1 (smoking), PPT2 (smoking) and KHDC3L (alcohol consumption). Evidence for a causal
effect of DNA methylation on survival was only observed in the SPEG gene region (HR per SD increase in
methylation score 1.28, 95% CI 1.14 to 1.43, P 2.12 × 10−05).
Conclusions: Part of the effect of smoking on survival in those with oropharyngeal cancer may be mediated by
methylation at the SPEG gene locus. Replication in data from independent datasets and data from HN5000 with
longer follow-up times is needed to confirm these findings.
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which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
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licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
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Introduction
Head and neck cancer (HNC) is the eighth most com-
monly diagnosed type of cancer, with over 12,000 new
cases diagnosed in the UK in 2015 [1]. Recently, oropha-
ryngeal cancer (OPC), a subtype of HNC, has shown a sig-
nificant increase in incidence in the UK. It has more than
doubled between 1990 and 2006, with a further doubling
since 2010 [2] and is affecting younger (< 45 years old)
populations with greater frequency [3]. OPC shows poor
survival rates, with the 5-year relative survival rate for the
more recently diagnosed oropharyngeal cases (between
2009 and 2013) estimated to be around 55–60% [4].
Several lifestyle and dietary factors as well as viral in-
fections have been implicated in altering both incidence
and prognosis for OPC [5–7]. Of particular importance
for both incidence [5, 8, 9] and prognosis of OPC [10]
are smoking, alcohol intake and HPV type 16 infection
(via sexual contact, including that of oral sex). Smoking
and, to a lesser extent, heavy drinking at the time of
diagnosis are both associated with increased incidence
and poor prognosis [10–12]. Interestingly, HPV16 in-
fection, while being a risk factor for OPC incidence,
is associated with improved prognosis [13–15]. One
study showed improved overall radically improved 4-
year survival for HPV-driven OPC (HR, 0.1; 95% CI
0.02–0.4; N, 448) [16].
DNA methylation signatures may also serve as valu-
able prognostic markers for cancer and can be measured
using rapid high-throughput approaches [17]. While sev-
eral whole-genome methylation assays have been per-
formed to define the DNA methylation signature of
tumour samples [18, 19], the ability to study cancers
through non-invasive sampling of body fluids is a rapidly
advancing development in cancer diagnostics and
prognosis. In particular, biomarkers identified in
blood hold promise as non-invasive prognostic tools
and may potentially be used to direct treatment if
shown to be informative proxies for cancer develop-
ment and prognosis [20].
Ultimately, smoking, alcohol consumption and HPV16
infection may influence DNA methylation patterns
which therefore have potential as novel exposure or
prognostic indicators in OPC [21–23]. Furthermore, as
epigenetic changes are a hallmark process of cancer [24],
DNA methylation patterns associated with cancer sur-
vival may provide insight into biologically relevant path-
ways. More specifically, these epigenetic changes may
act as intermediates on the pathways by which exposures
influence survival. For example, as viral infections are
thought to play an important role in altering epigenetic
processes [25–27], these may serve as a mechanism by
which having a HPV16 infection might confer a protect-
ive effect over not having one. However, distinguishing a
causal mediating role of these epigenetic changes from
other explanations such as confounding and reverse
causation is challenging and requires more advanced
methodological techniques, including the use of Mendel-
ian randomization (MR) [28–30]. MR is an approach
which uses genetic variants strongly associated with
modifiable exposures to appraise the causal effect of the
exposures on disease risk. This approach has been ex-
tended to interrogate the causal relationship with mo-
lecular intermediates such as DNA methylation [29, 30].
In the setting of a large prospective head and neck can-
cer cohort (the Head and Neck 5000 Study), we profiled
DNA methylation from whole blood in 443 participants
with oropharyngeal cancer close to time of diagnosis and
prior to treatment starting. We aimed to perform
epigenome-wide association analyses (single-site EWAS
and differentially methylated region [DMR] analysis) of
the main prognostic factors for oropharyngeal cancer (al-
cohol, smoking and HPV16 infection) as well as survival
up to ~ 3 years. We then assessed overlap between the
DNA methylation profiles related to these prognostic fac-
tors and survival. Where there was evidence of a shared
signal, we performed Mendelian randomization analysis to
appraise the causal effect of DNA methylation in mediat-
ing the effect of these factors on survival.
Results
Baseline characteristics of samples with epigenetic data,
compared to the wider HNC and OPC samples in
HN5000 are shown in Table 1. Notably, the proportion of
those with OPC under the age of 60 is higher than those
with other sub-types of HNC, and the degree to which
those with OPC differ to other HNC sub-types with re-
spect to HPV16 E6 positivity is substantial. Table 1 shows
that the demographics of those who were selected to have
DNA methylation profiled were sufficiently representative
of others with the OPC sub-type in HN5000 with respect
to exposure to prognostic factors, albeit not necessarily
representative of HNC as a whole.
Smoking single-site EWAS and DMR associations
Our single-site EWAS of ever vs never smokers (303 ever
smokers vs 106 never smokers) revealed 52 CpG site asso-
ciations annotated to 27 unique loci (P < 5.7 × 10−8, Bon-
ferroni adjusted P < 0.05 for 862,491 tests) (Fig. 1). The
CpG site cg05575921, which annotates to the AHRR gene
region, was most strongly associated (P < 1.48 × 10−40)
and also showed the largest effect size of − 29.5% differ-
ence (95% CI − 26.9 to − 32.1%) to in methylation be-
tween ever and never smokers. Forty-nine CpG sites had
lower DNA methylation in ever smokers, with a mean dif-
ference in methylation of − 8.3% (SD, 5.1%; range, − 29.5
to − 2.2%). The three remaining CpG sites had higher
methylation in smokers, with a mean difference of 7.7%
(SD, 4.2%; range, 4.7 to 12.6%). Supplementary Table 1
Langdon et al. Clinical Epigenetics           (2020) 12:95 Page 2 of 19
provides the complete list of all CpGs that were dif-
ferentially methylated below a less stringent threshold
of P = 2.4 × 10−7. Of the results presented in this
table, 37.5% (24/64 CpGs) were present on the EPIC
array but not its 450K predecessor (which provided
measurements for 485,512 CpG sites; 93% of these
are measured by the EPIC array).
In the differentially methylated region (DMR) analysis (see
the “Methods” section) of ever vs never smoking, 166
unique DMRs containing 617 measured CpGs and annotat-
ing to 156 gene regions were discovered (Fig. 3). The DMR
with the strongest association consisted of 3 measured CpGs
(cg21566642, cg01072057 and cg13903162) and was located
at Chr2:233284661-233285290, an intergenic CpG island on
2q37.1 (P 1.13 × 10−46).
Alcohol consumption single-site EWAS and DMR
associations
The EWAS of alcohol consumption (median 22.5 units/
week in 303 alcohol drinkers and 106 non-drinkers) re-
vealed 3 CpG site associations annotated to 3 unique
genes (P < 5.7 × 10−8) (Fig. 2). The association with the
Fig. 1 Manhattan plot of EWAS of ever vs never smoking, showing CpG sites within DMRs in red. Each dot represents the EWAS result for a
single CpG site, plotting – log10 (P) (y-axis) against the genomic position of the CpG site (x-axis). The horizontal red line is at P < 5.7 × 10
−8 and
represents the value below which CpG sites were considered to have good evidence of association with smoking
Table 1 Comparison of patient demographics in OPC samples selected for methylation data extraction; all samples in HN5000
identified as OPC and all samples in HN5000
Variable OPC in HN5000 with methylation data and
complete phenotype data (N = 409)
OPC in HN5000 (N = 1909) All HN5000 (all sub-types) (N = 5392)
ICD group (% oropharynx) 100 100 35.4
Sex (% female) 27.0 21.9 27.2
Age (% < 60) 58.4 52.4 42.7
Smoking (% never smoked) 27.1 28.0 24.6
Alcohol (% non-drinker) 25.9 26.6 28.4
HPV16 E6 (% negative) 33.3 32.3 72.0
Survival (% died, prior to 30/09/2017) 26.2 24.2 28.0
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smallest P value was cg06690548 (P 8.3 × 10−16), anno-
tating to the SLC7A11 gene region. This CpG site also
showed the largest effect size of − 0.10% difference in
methylation per unit increase in alcohol. All results
below a multiple testing threshold of 2.4 × 10−7 are
shown in Supplementary Table 2. Of the results pre-
sented in this table, 40% (2/5 CpGs) were present on the
EPIC array but not the 450K predecessor.
In the DMR analysis of alcohol consumption, 40
unique DMRs containing 238 measured CpGs and an-
notating to 34 gene regions were identified (Fig. 2).
The DMR with the smallest P value was a region of 2
CpGs (cg06690548 and cg13903162) found at Chr4:
139162808-139163020 (P, 1.45 × 10−10), annotated to
the SLC7A11 gene region.
HPV16 E6 serology single-site EWAS and DMR
associations
In the EWAS analysis of HPVE6 seropositivity (272 sero-
positive for HPV16 E6 vs 136 seronegative for HPV16
E6), no CpGs passed the P value threshold after Bonfer-
roni correction for 862,491 tests (P < 5.7 × 10−8) (Fig. 3).
At a suggestive threshold of 2.4 × 10−7, only 1 CpG site
(cg26738437; P, 1.3 × 10−7) was found, annotating to the
CCL16 gene. This probe is not found on the 450K array.
Methylation was on average 2.3% lower in HPV16 E6
seropositive participants than controls.
In the DMR analysis of HPV16 E6 seropositivity, 31
unique DMRs pertaining to 158 CpGs and annotating to
38 gene regions were identified (Fig. 3). The most associ-
ated DMR was a region of 13 CpGs found at Chr5:
110062343-110062838 (P, 4.10 × 10−6), annotating to
the TMEM232 gene region.
Survival (~ 3-year) single-site EWAS and DMR associations
Of the participants with OPC who had methylation data
available, 26.2% had died at the time of censoring (~ 3
years post-diagnosis). In the single-site analysis of sur-
vival (model 1, adjusting for age, sex and surrogate vari-
ables obtained by SVA [31]), 3 CpGs annotated to 3
unique loci showed association with survival below a
Bonferroni threshold for 862,491 tests (P < 5.7 × 10−8)
(Fig. 4). One of the 3 CpGs passing our multiple testing
correction showed lower methylation in those who died,
while the other 2 CpG sites passing multiple testing cor-
rection showed higher methylation in those who died.
The site showing lower methylation was also the most
strongly associated with survival, annotating to PAQR3
and showing the largest effect size among our top hits
(cg25864218; β [difference in methylation between those
Fig. 2 Manhattan plot of EWAS of alcohol consumption, showing CpG sites within DMRs in red. Each dot represents the EWAS result for a single
CpG site, plotting – log10 (P) (y-axis) against the genomic position of the CpG site (x-axis). The horizontal red line is at P < 5.7 × 10
−8 and
represents the value below which CpG sites were considered to have good evidence of association with alcohol consumption
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who died before 30th September 2017]: − 2.54%; P 1.04
× 10−9). Of the 2 sites showing higher methylation in
those who died, the mean difference in methylation was
0.3% (SD, 0.27%; range, 0.11 to 0.49%). These sites anno-
tated to DNAH11 (cg07377396; β, 0.49%; P, 3.39e−8)
and MYBPC1 (cg12151015; β, 0.11%; P, 7.51 × 10−9). All
results below a suggestive multiple testing threshold of
2.4 × 10−7 are shown in Supplementary Table 3. Of the
results presented in this table, 47% (7/15) were novel as-
sociations, pertaining to the EPIC array vs the 450K pre-
decessor. A heatmap showing the correlation between
all CpG sites below the suggestive multiple testing
threshold across alcohol consumption, HPV16E6 sero-
positivity, smoking and survival (model 1) EWAS can be
seen in Supplementary Figure 1.
In the DMR analysis of survival (model 1), 142 unique
DMRs pertaining to 805 CpGs and annotating to 153
gene regions were identified (Fig. 4). The DMR with the
lowest P value was a region of 10 CpGs found at Chr17:
33814297-33814897 (P, 5.26 × 10−21), annotating to the
CDK16 gene region.
In our post-hoc sensitivity analyses, we found SVs sig-
nificantly correlated (Pearson’s product-moment coeffi-
cient P value < 0.05) with treatment type, TNM stage
and neutrophil-to-lymphocyte ratio, a marker of im-
mune profile. Six SVs were associated with laser surgery
(Supplementary Figure 2), 3 with surgical removal of an
OPC primary (Supplementary Figure 3), 2 with neck re-
section surgery (Supplementary Figure 4), 6 with telether-
apy (Supplementary Figure 5), 4 with chemotherapy
(Supplementary Figure 6), 4 with chemoradiotherapy
(Supplementary Figure 7), 9 with TNM stage (Supplemen-
tary Figure 8) and 4 with neutrophil-to-lymphocyte ratio
(Supplementary Figure 9). Furthermore, despite the blood
being taken prior to treatment, all 63 SVs explained 29.5%
of the phenotypic variance for laser surgery, 15.5% for sur-
gical removal of an OPC primary, 15.0% for neck resection
surgery, 20.9% for teletherapy, 21.2% for chemotherapy,
22.3% for chemoradiotherapy, 27.8% for TNM stage and
51.4% for neutrophil-to-lymphocyte ratio.
In the single-site analysis of survival with additional ad-
justment for HPV16E6 seropositivity, smoking status and
alcohol intake, 6 CpGs annotated to 4 unique loci showed
a P value of association below the Bonferroni threshold (P
< 5.7 × 10−8) (Fig. 5). Our most associated site (P, 1.22 ×
10−8), cg25864218, annotates to the PAQR3 gene region.
This site also showed the largest effect size of a − 2.5% dif-
ference in methylation between those who died and those
Fig. 3 Manhattan plot of EWAS of HPV16E6 seropositivity, showing CpG sites within DMRs in red. Each dot represents the EWAS result for a
single CpG site, plotting – log10 (P) (y-axis) against the genomic position of the CpG site (x-axis). The horizontal red line is at P < 5.7 × 10
−8 and
represents the value below which CpG sites were considered to have good evidence of association with HPV16 E6 seropositivity
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who survived. Two CpG sites, cg25864218 (annotating to
PAQR3, above) and cg12151015 (annotating to MYBPC1),
showed an association with survival across both adjusted
and unadjusted analyses. Other CpGs passing our multiple
testing correction which were annotated to genes included
MYBPC1 (cg12151015; β, 0.11%; P, 2.59 × 10−8), GRIN2A
(cg08204867; β, − 0.16%; P, 2.87 × 10−8) and IL15
(cg26269613; β, 0.67%; P, 5.34 × 10−8). All results below a
suggestive multiple testing threshold of 2.4 × 10−7 are
shown in Supplementary Table 4. Interestingly, of the re-
sults presented in this table, all 23 were novel associations,
pertaining to the EPIC array vs the 450K predecessor.
In the DMR analysis of survival (model 2), 157 unique
DMRs pertaining to 874 CpGs and annotating to 177
gene regions were identified (Fig. 5). The DMR with the
lowest P value was a region of 12 CpGs found at ChrX:
47077168-47077877 (P, 1.08 × 10−21), annotating to the
CDK16 gene region.
Overlap between risk factor and survival DMRs
Eighteen unique CpGs overlapped between all smoking
DMRs and survival (EWAS model 1) DMRs, belonging
to 3 unique DMRs (annotated to GFI1, SPEG and
PPT2); five CpGs overlapped between all alcohol DMRs
and survival (EWAS model 1) DMRs, all pertaining to a
single DMR (annotated to KHDC3L) (Supplementary
Table 5). No CpGs overlapped between the HPV DMRs
and survival (EWAS model 1) DMRs. Strength of correl-
ation between CpGs within the overlapping DMRs can
be seen in Fig. 6.
Of the 18 CpGs which overlapped between smoking
and survival, 15 possessed mQTL proxies in summary
data of the genetic determinants influencing methylation
levels in 5101 individuals from the Generation Scotland
cohort. Of the 5 CpGs which overlapped between alcohol
and survival, 3 possessed mQTL proxies in the Generation
Scotland summary data (Supplementary Table 5).
Mendelian randomization analysis of the effect of DNA
methylation on OPC survival
Table 2 and Fig. 7 show the results of the MR analysis of
DNA methylation on 3-year survival in HN5000, using
mQTL-proxied DNA methylation at CpG sites associ-
ated with both smoking and survival. Results indicate a
causal effect of decreased DNA methylation on survival
at the SPEG gene locus (Table 2; Chr2:22035443-
Fig. 4 Manhattan plot of EWAS of survival (model 1, not adjusted for smoking, alcohol consumption and HPV16E6 seropositivity), showing CpG
sites within DMRs in red. Each dot represents the EWAS result for a single CpG site, plotting – log10 (P) (y-axis) against the genomic position of
the CpG site (x-axis). The horizontal red line is at P < 5.7 × 10−8 and represents the value below which CpG sites were considered to have good
evidence of association with survival
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22036041; HR, 1.28; 95% CI, 1.14 to 1.43), suggesting
that DNA methylation may mediate part of the associ-
ation seen between smoking and increased survival at
this gene region. The GFI1 and PPT2 (Table 2) gene re-
gions appear to show no consistent evidence of a causal
effect of DNA methylation on survival.
Table 3 and Fig. 8 show the results of the MR analysis
of DNA methylation on 3-year survival in HN5000,
using mQTL-proxied DNA methylation at CpG sites as-
sociated with alcohol intake and survival. In our analysis,
there appears to be no consistent evidence for a causal
effect of DNA methylation on survival at the KHDC3L
gene locus (Chr6:74072255-74072376).
Discussion
By undertaking single-site EWAS and DMR analyses in
whole blood, we identified a number of sites in the gen-
ome where DNA methylation may mediate the effect of
three prognostic factors (smoking, alcohol and HPV16
positivity) and survival from oropharyngeal cancer. We
identified CpG sites and DMRs associated with smoking
and alcohol consumption, but none associated with HPV
seropositivity. We also identified 6 CpGs associated with
survival at 3 years post-diagnosis. Twenty-three CpGs at
4 DMRs were identified in both analyses of risk factor
and of survival. MR analysis was conducted to assess
whether DNA methylation at the identified sites were
causally implicated in relation to OPC survival. We
found preliminary evidence to support this mediation
pathway between smoking and OPC survival at the
SPEG gene locus.
In relation to smoke exposure, our results replicate
loci previously reported in literature, notably in AHRR
and PRSS23 [21, 32]. The effect size seen in our EWAS
for cg05575921 (AHRR) (29.5%) is markedly stronger
compared to the largest published smoking EWAS ana-
lysis; Joehanes et al. [21] report 18% lower methylation
for between current and never smokers (P, 4.60 × 10−26).
A potential explanation of this finding could be that our
analysis was conducted in a case-only setting where
smoking is one of the predominant risk factors for HNC,
and so smoking intensity is likely to be higher compared
to non-cancer smoking populations. We completed a
lookup of our top smoking CpG sites (P < 5.7 × 10−8),
using the EWAS Catalog (http://www.ewascatalog.org/)
online tool to compare whether our effect sizes were
Fig. 5 Manhattan plot of EWAS of survival (model 2, adjusted for smoking, alcohol consumption and HPV16E6 seropositivity), showing CpG sites
within DMRs in red. Each dot represents the EWAS result for a single CpG site, plotting – log10 (P) (y-axis) against the genomic position of the
CpG site (x-axis). The horizontal red line is at P < 5.7 × 10−8 and represents the value below which CpG sites were considered to have good
evidence of association with survival
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consistently stronger than other published smoking
EWAS findings (Supplementary Table 6). Of our 52 sites
below a conservative Bonferroni correction, 20 had not
been previously reported in published EWAS. The other
32 CpG sites which had previously been reported in
literature showed consistently larger effect estimates in
response to smoking, in our analysis, when compared to
a weighted mean (weighted by sample size) of published
EWAS beta values.
Using the same EWAS Catalog resource, we also
attempted to determine those associations below our
multiple testing threshold for all of our EWAS (Supple-
mentary Table 6). All 5 associations found in our alcohol
consumption analysis had not been previously reported in
published EWAS of alcohol consumption, likely because
they are not measured on the 450k array. SLC7A11, the
gene annotated to our top CpG site for the alcohol con-
sumption analysis, is essential for glutathione synthesis, a
component of the KEAP1-NRF2-CUL3 axis and strongly
associated with poor prognosis in The Cancer Genome
Atlas (TCGA) HNC cohort [33, 34].
For our 3-year survival EWAS, none of the top associ-
ations at P < 5.7 × 10−8 in either model have previously
been reported in published studies. Both survival EWAS
models gave a top hit annotating to the PAQR3 gene
(cg25864218). Aberrant promotor methylation at this
Fig. 6 Heatmap showing correlation between differentially-methylated regions (Sidak < 0.05) for each prognostic factor (alcohol consumption,
HPV16 E6 seropositivity and smoking) and survival EWAS (model 1 ~ 3-year survival adjusted for age sex and surrogate variables). Strength of
association is shown by depth of colour; deeper red denotes a stronger phenotypic association with DMR
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gene has been shown to be associated with prostate cancer
[35], with the gene itself an established tumour suppressor
[36]. Within the context of HNC, PAQR3 has been associ-
ated with tumorigenesis in oesophageal cancer [37, 38],
though to our knowledge no current literature has exam-
ined whether this gene affects oropharyngeal cancer
specifically.
In four gene regions, DNA methylation signals were
found to overlap between respective prognostic factors
and survival: SPEG (smoking), GFI1 (smoking), PPT2
(smoking) and KHDC3L (alcohol consumption). The
SPEG gene shows specificity to vascular smooth muscle
cells—the major cell type in blood vessel walls, in which
smoking has been shown to produce abnormal function
throughout the human body [39]. Functional annotations
show the SPEG gene to be essential for cardiac function in
particular, with deficiency of this gene reported to result
in heart failure [40]. The GFI1 gene encodes a zinc finger
protein which appears to play a role in diverse develop-
mental contexts such as haematopoiesis and oncogenesis
by contributing to the control of histone modifications to
silence gene promotors [41]. Parmar et al. suggest that
smoking-related epigenetic changes at GFI1 are robustly
associated with cardiometabolic risk factors, with lower
methylation at GFI1 CpGs associated with elevated trigly-
ceride levels [42]. The PPT2 gene encodes a protein which
removes thioester-linked fatty acyl groups from various
substrates, including S-palmitoyl-CoA [43]. A genetic vari-
ant within this gene region appears to be robustly associ-
ated with the ratio of forced expiratory volume in the first
second (FEV1) to forced vital capacity (FEV1/FVC, an indi-
cator of airflow obstruction) in a replicated GWAS of over
20,000 individuals from Cohorts for Heart and Aging Re-
search in Genomic Epidemiology (CHARGE) consortium
studies [44]. Finally, the KHDC3L gene shows specificity
to oocytes and is thought to play a role in the global estab-
lishment of methylation in these cells. However, the
mechanistic pathway through which these changes occur
has yet to elucidated, due in part to the novel discovery of
KHDC3L’s effect on global methylation currently being a
novel discovery [45].
The tight confidence intervals and consistent direction
of effect between MR Egger and IVW estimates for the
SPEG locus provide us with greater confidence in a reli-
able IV and sufficient statistical power to demonstrate
preliminary evidence of a causal effect of methylation at
this locus on reduced survival. A lookup in the BIOS
QTL Browser (https://genenetwork.nl/biosqtlbrowser/)
confirms 20 cis-expression quantitative trait methyla-
tions (eQTMs) showing evidence of correlation between
gene expression and methylation at this locus in whole
blood, though further work evaluating tissue-specific ex-
pression is required. The role of this gene in cardiac
function is of interest since cardiovascular disease is a
common comorbidity of people with HNC [46, 47],
where the 5-year incidence of non-cancer survival is 13%
[48]. Our finding may have clinical relevance for OPC
and prognostic studies more broadly if methylation and/
or expression of SPEG is confirmed to be causally re-
lated to with survival. For example, there may be scope
to target DNA methylation at this gene region thera-
peutically if a proportion of the effect of smoking on
mortality is mediated through this pathway. However,
appropriate validation and replication studies need to be
conducted to establish the true effect of smoking-related
DNAm at the SPEG gene region on mortality. Further-
more, quantification of the proportion of smoking-
related mortality risk at this gene region will be crucial
in determining whether targeting it is a cost-effective
therapeutic target.
Table 2 Mendelian randomization (MR) analysis results, assessing epigenetic mediation between smoking status and ~ 3-year
survival at the SPEG gene (chromosome 2:220325443-220326041), GFI1 gene (chromosome 1:92946132-92947588) and PPT2 gene
(chromosome 6:32120895-32120907). Inverse-variance weighted (IVW) and MR Egger results, adjusted for genetic correlation
between mQTLs, are reported as hazard ratios with 95% confidence intervals
Region (gene) MR method SNPs HR 95% CI P
All DMR CpGs
Chr2:220325443-220326041 (SPEG) IVW 17 1.28 1.14 to 1.43 2.12 × 10−05
Chr2:220325443-220326041 (SPEG) MR Egger 17 1.28 1.18 to 1.38 4.04 × 10−10
Chr1:92946132-92947588 (GFI1) IVW 8 0.74 0.60 to 0.93 7.9 × 10−03
Chr1:92946132-92947588 (GFI1) MR Egger 8 2.65 0.77 to 9.12 0.12
Chr6:32120895-32120907 (PPT2) IVW 8 0.82 0.52 to 1.30 0.40
Chr6:32120895-32120907 (PPT2) MR Egger 8 1.68 0.27 to 10.38 0.58
Sentinel CpG only
cg06084174 (SPEG) IVW 3 1.14 0.90 to 1.45 0.29
cg06338710 (GFI1) Wald ratio 1 0.93 0.47 to 1.85 0.84
cg17113856 (PPT2) IVW 2 0.67 0.37 to 1.22 0.19
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Fig. 7 Forest plots showing SNP-specific and overall IV hazard ratio estimates (95% CI) for Mendelian randomization analyses of smoking-
associated methylation at 3 gene loci (GFI1, PPT2, SPEG), against 3-year survival in oropharyngeal cancer
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To our knowledge, this is the first EWAS study inves-
tigating oropharyngeal cancer survival using a Cox
proportional-hazards model to investigate DNA methy-
lation in relation to incident survival at ~ 3 years. A key
strength of the study relates to the use of the EPIC array
which profiles methylation at approximately twice as
many CpG sites as its 450k predecessor. Across the
EWAS of smoking, alcohol, HPV and both survival
models, 39.4% of the CpG sites at P < 2.4 × 10−7 were
specific to the EPIC array. However, proportionally, our
results suggest that associations are not enriched with
the inclusion of novel enhancer region CpGs from this
array. A one-sided Fisher’s exact test for enrichment of
EPIC probes vs 450K probes in CpG sites below P 2.4 ×
10−7 confirms this; P > 0.99.
The gold standard to identify HPV-driven tumours is
through detection of HPV DNA and RNA. A potential
limitation of this study is that our EWAS of HPV16 posi-
tivity is based on measures of serological response to HPV
infection rather than p16 and/or in-situ hybridisation
(ISH), which are typically used in clinical practice in the
UK [2]. P16 alone will tend to overestimate the number of
HPV-driven tumours, as some tumours that are not HPV-
driven can still be p16-positive [49]. However, HPV-
driven OPC mount an early and marked serological
response that has good agreement with tissue markers, in-
dicating an HPV-driven tumour [50]. In HN5000, current
information on p16 status relies solely on clinical informa-
tion rather than being a baseline measurement across all
study centres. Although HN5000 are in the process of
Table 3 Mendelian randomization (MR) analysis results, assessing epigenetic mediation between alcohol consumption and ~ 3-year
survival at the KHDC3L gene (chromosome 6:74072255-74072376). Inverse-variance weighted adjusted for genetic correlation
between mQTLs (IVW), MR Egger and Wald ratio results are each reported as hazard ratios with 95% confidence intervals
Region (gene) MR method SNPs HR 95% CI P
All DMR CpGs
Chr6:74072255-74072376 (KHDC3L) IVW 4 1.17 0.70 to 1.97 0.55
Chr6:74072255-74072376 (KHDC3L) MR Egger 4 0.89 0.27 to 2.98 0.85
Sentinel CpG only
cg19146112 (KHDC3L) Wald ratio 1 1.17 0.54 to 2.53 0.68
Fig. 8 Forest plot showing the SNP-specific and overall IV hazard ratio estimates (95% CI) for Mendelian randomization analyses of alcohol-
associated methylation at the KHDC3L gene locus, against 3-year survival in oropharyngeal cancer
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carrying out p16 on many participants with OPC, this is
not currently available, and so there are considerable miss-
ing data for this measure. Additionally, very few centres
performed confirmatory tests to the serology which was
conducted at baseline, such as ISH. There is good agree-
ment between serology and tissue measures of HPV-
driven tumours; studies have found little difference in the
number of individuals confirmed as having HPV-driven
OPC between serology and p16 [50], with p16 alone more
prone to overestimate the number of HPV-driven cases.
Given a current lack of p16/ISH data in HN5000, we
remain confident in our method of viral diagnosis of OPC.
Most HPV-driven OPC are caused by the HPV16 sero-
type, to the extent that presence of antibodies specific to
HPV16 E6 > 1000 MFI are widely accepted as a reliable
measure of “HPV-driven” OPC [51]. However, an esti-
mated 3% of HPV-driven OPC are caused by other HPV
sub-types. We were careful to define the HPV EWAS as
an EWAS of ‘HPV16 E6 seropositivity’ to reflect the
HPV detection method and sub-type specificity. An
epigenome-wide investigation in relation to a broader
phenotype of HPV seropositivity, including other HPV
sub-types, may have identified other CpG sites which
were not identified in relation to E6, although this is
unlikely given the particularly low proportion of HPV-
driven OPC not caused by HPV16.
Collider bias may influence associations between our
prognostic factors and survival in a case-only setting [52,
53]. HPV, smoking and alcohol are all associated with
OPC incidence. By only examining OPC cases, incidence
is conditioned on, potentially inducing an association be-
tween HPV, smoking, alcohol and any unmeasured con-
founding (including, but not limited to, any possible
factor independently associated with OPC incidence). By
inducing artificial associations between risk factors and
confounding in this way, conducting an EWAS stratified
by cases may generate spurious associations between
methylation changes which do not affect survival, and
survival.
Some of our MR analyses highlight potential violations
of its methodological assumptions. Primarily, those ana-
lyses where the MR Egger estimate shows an effect in the
opposite direction to the IVW estimate (GFI1, PPT2,
KHDC3L) could indicate an IV where one or more of the
genetic variants proxying methylation is biasing the effect
due to horizontal pleiotropy. However, for each of these
analyses, the MR Egger intercept test of heterogeneity (ex-
plained elsewhere [54, 55]) spans 0 (GFI1 intercept − 0.25,
95% CI −0.54 to 0.05, P value 0.10; PPT2 intercept − 0.18,
95% CI − 0.58 to 0.23, P value 0.40; KHDC3L intercept
0.07, 95% CI − 0.09 to 0.23, P value 0.37), indicating that
directional pleiotropy is not causing the difference be-
tween the MR Egger and IVW estimates. Consequently, a
possible explanation of the opposing directions seen
between MR Egger and IVW estimates is that, in this in-
stance, the low power of the MR Egger tests has simply
generated imprecise effect estimates.
One notable limitation of our MR analysis is that it is
likely particularly conservative; we assessed overlap be-
tween prognostic factor DMRs and survival DMRs only
if they surpassed our multiple correction threshold in
both analyses. We opted for this approach to improve
confidence that regional methylation was associated with
both a prognostic factor and survival. However, in order
to reduce the possibility that regional methylation was
only associated with a prognostic factor (and only
spuriously associated with survival), we may have missed
genuine causal mediation at less-stringent P value
thresholds.
Conclusion
Within the context of OPC, we found novel epigenetic
biomarkers measured by the EPIC array in whole blood
to be associated with the prognostic factors of smoking
and alcohol, and with survival. Of these biomarkers, we
used overlapping signals between prognostic factor and
survival analyses to then conduct MR analysis to ap-
praise the causal role of DNA methylation. Using an
IVW approach to investigate the causal effect of DNA
methylation at the identified sites, we found that a col-
lection of CpGs located within a DMR associated with
smoking (located at Chr2:220325443-220326041; anno-
tating to the SPEG gene) showed some evidence of a
causal effect on decreased survival (HR, 1.28; 95% CI,
1.14 to 1.43; P, 2.12 × 10−05). DNA methylation at this
locus could potentially mediate some of the association
between smoking and OPC survival. To strengthen the
validity of these findings, replication analyses and a
longer follow-up period in Head and Neck 5000 are
recommended.
Methods
Study population
The study population for this analysis was individuals en-
rolled in the Head and Neck 5000 (HN5000) clinical co-
hort study. Participants for our study were selected from
the wider pool of individuals in HN5000 (N, 5392) based
on an ICD-10 coding of oropharynx (CO1, CO5, CO9,
C10.0-2, C10.3, C10.8 and C10.9; N, 1909/5392), availabil-
ity of OncoChip genotype data generated previously (N,
1034/1909; necessary to conduct the Mendelian
randomization analysis—see the “mQTL associations with
survival” subsection below) [56], baseline questionnaire
and data capture information (see below) and the avail-
ability of blood samples taken at baseline (N, 448/1034).
Full details of the study methods and overall popula-
tion are described in detail elsewhere [57, 58]. Briefly,
between April 2011 and December 2014, 5511
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individuals with HNC were recruited from 76 centres
across the UK. All people with a new diagnosis of HNC
were eligible to join the study and were recruited before
or within a month of their cancer treatment commen-
cing. Individuals with cancers of the pharynx, mouth,
larynx, salivary glands and thyroid were included, while
those with lymphoma, tumours of the skin or a recur-
rence of a previous head and neck cancer were excluded
from the study.
Local research nurses obtained informed consent from
individuals, which included agreement to: collect, store
and use biological samples; obtain samples of stored tis-
sue; carry out genetic analyses and collect clinical informa-
tion from hospital notes and survival data through record
linkage. Ethics approval for this study was granted by the
National Research Ethics Committee (South West
Frenchay Ethics Committee, reference 10/H0107/57, 5th
November 2010) and approved by the research and devel-
opment departments from participating NHS Trusts.
Baseline data collection
Participants were asked to complete a series of three self-
administered questionnaires at recruitment, enquiring
about: (1) social and economic circumstances, overall
health and lifestyle behaviours; (2) physical and psycho-
logical health, well-being and quality of life and (3) past sex-
ual history and behaviours [57]. Information on diagnosis,
treatment and co-morbidity was recorded on a short data
capture form using questions based on a national audit [51,
59]. Diagnoses were coded using the International Classifi-
cation of Diseases (ICD) version 10 [60, 61], and clinical
staging of the tumour was derived based on the American
Head and Neck Society TNM staging [52, 62].
Research nurses collected a blood sample from all
consenting participants at recruitment, prior to treat-
ment, unless treatment was their diagnostic procedure
[58]. These were then sent to the study centre labora-
tory at ambient temperature for processing. The
blood samples were centrifuged at 3500 rpm for 10
min and the buffy coat layer used for DNA extrac-
tion. Any additional samples from the same partici-
pant were frozen and stored at – 80 °C.
Assessment of tobacco, alcohol and HPV infection
Detailed information on tobacco and alcohol history was
obtained at baseline via the self-administered question-
naire. Participants were asked about their current smok-
ing and drinking status and their use of tobacco and
alcohol products prior to receiving their HNC diagnosis.
Among smokers, information on age at smoking initi-
ation and number of years of smoking was obtained.
The questionnaire differentiated between use of ciga-
rettes, hand-rolled cigarettes, cigars and smokeless to-
bacco, whereby a cigar was considered equivalent to four
cigarettes. From this information, participants were
dichotomised into ever and never smokers. Ever smokers
were defined as those who smoked at the equivalent of
at least 1 tobacco product a day per year or ≥ 100 ciga-
rettes in their lifetime. Never smokers were those who
reported not smoking in any of the questions answered.
Respondents were asked to report their average weekly
alcohol consumption of a range of beverage types (wine,
spirits and beer/larger/cider) before they were diagnosed
with cancer. From these measures, we derived an aver-
age intake of alcohol consumption in units per week.
HPV serologic testing (HPV16 E6, E7, E1, E2, E4 and
L1) was conducted at the German Cancer Research Cen-
ter (DKFZ, Heidelberg, Germany) using glutathione S-
transferase multiplex [63]. Median fluorescence intensity
(MFI) values were dichotomized to indicate HPV16 E6
seropositivity using a cut-off of ≥ 1000 MFI [64]. E6
seropositivity is known to be a marker of current infec-
tion and has a high sensitivity and specificity for
HPV16-driven oropharyngeal cancer [65].
Study follow-up and survival
Regular updates were received from the NHS Central
Register (NHSCR) and the NHS Information Centre
(NHSIC) notifying on subsequent cancer registrations
and survival among cohort members in the Head and
Neck 5000 study. Recruitment for the study finished in
December 2014 and follow-up information on survival
status was obtained on 30th September 2017, resulting
in at least 2.75 years of follow-up for all participants.
DNA methylation
Data generation
Following extraction, DNA was bisulphite-converted
using the Zymo EZ DNA MethylationTM kit (Zymo, Ir-
vine, CA, USA). Genome-wide methylation data were
generated using the Infinium MethylationEPIC Bead-
Chips (EPIC array) (Illumina, USA) according to the
manufacturer protocol. The arrays were scanned using
an Illumina iScan (version 2.3).
Pre-processing
Raw data files (IDAT files) were pre-processed using the R
package meffil (https://github.com/perishky/meffil/) [56].
We used the same R package to perform quality control
and normalisation [66]. Sample mismatches and outliers
were identified and removed based on allosome methyla-
tion (N, 2 incorrect sex prediction; N, 3 outliers) and 65
genotype probes, which were compared with SNP-chip
data from the same individual (N, 3 exclusions). Sample
outliers were also identified based on control probe (bisul-
fite 1 and bisulfite 2) mean outliers (N, 2 exclusions), out-
liers for median intensity methylated vs unmethylated
signal for all control probes (N, 2 exclusions), detection P
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value (N, 2 exclusions based on high proportion of un-
detected probes [> 10% of probes failing a detection P
value > 0.01]) and low bead numbers (N, 1 exclusions).
Overall, 443 samples passed QC. Following QC, functional
normalization was used to separate biological variation
from technical variation [57, 67]. Data were normalised
using 5 control probe principal components derived from
the technical probes. The Infinium EPIC array pipeline de-
tects the proportion of molecules methylated at each CpG
site on the array. For the samples, the methylation level at
each CpG site was calculated as a beta value (β), which is
the ratio of the methylated probe intensity and the overall
intensity and ranges from 0 (no cytosine methylation) to 1
(complete cytosine methylation).
EWAS
Epigenome wide association study (EWAS) analysis was
conducted to identify associations between DNA methyla-
tion and (1) alcohol consumption, (2) smoking status and
(3) HPV16E6 seropositivity. EWAS were conducted in mef-
fil, using a linear regression model of DNA methylation
regressed on the prognostic factors, adjusting for age, sex,
surrogate variables obtained by SVA [31] and the other
prognostic factors (e.g. for alcohol intake, adjusting for
smoking and HPV16E6). Of the 443 individuals who passed
QC, the number of individuals with complete phenotype
data for alcohol intake, smoking status and HPV16E6 sero-
positivity with which to conduct an EWAS was 409 as of
the 2018, version 2.3 release of HN5000 data. All of these
samples possessed information on survival status.
An EWAS for survival from recruitment (last participant
recruited December 2014)—September 2017 (or time of
censoring; whichever occurred first)—was conducted
using code adapted from the meffil R package [56, 66].
Cox proportional-hazards models were employed: model
1 adjusting for age, sex and surrogate variables obtained
by SVA [31]; model 2 adjusting for age, sex, surrogate var-
iables obtained by SVA [31], HPV16E6 seropositivity,
smoking status and alcohol intake. Death from any cause
was used as the failure variable and time to death (or cen-
soring) in days as the time variable.
Due to the large number of tests conducted in our
EWAS, we employed a Bonferroni correction to derive a
conservative P value threshold of 5.7 × 10−8 (0.05/862491
independent tests) to determine those sites showing
strong evidence of association with our risk factor of inter-
est or survival, respectively. We also used the alpha value
calculated for the Illumina 450K array (the predecessor to
the MethylationEPIC array) as a P value threshold of 2.4 ×
10−7 for suggestive evidence of association [68].
DMR analysis
Adjacent probes on the Illumina arrays are often highly
correlated; therefore, differentially methylated regions
(DMRs) may reveal regions of DNA where CpGs are as-
sociated with risk factors and survival. Following each
EWAS, we conducted DMR analysis using the dmrff R
package [59, 69]. This analysis identified regions (> 1
CpG site per region) enriched for low P values (P <
0.05), corrected for dependencies between other CpG
sites in the DMR and adjusted for multiple testing.
Sensitivity analysis
To ensure our SV analysis was adequately adjusting for
factors which influenced our survival EWAS, we system-
atically assessed the correlation of SVs with treatment
type, TNM stage and immune profile post-hoc. Add-
itionally, we appraised the amount of phenotypic vari-
ance the SVs explained in the above factors which were
available in HN5000 (laser surgery, surgical removal of
an OPC primary, neck resection surgery, teletherapy,
chemotherapy, chemoradiotherapy, TNM stage and
neutrophil-to-lymphocyte ratio).
Generation Scotland methylation quantitative trait loci
DNA methylation can be influenced by genetic sequence
variations, such that individual genotypes at a given
locus may result in different patterns of DNA methyla-
tion due to allele-specific methylation [70–72]. Such
sites, called methylation quantitative trait loci (mQTLs),
can influence the methylation pattern across an ex-
tended genomic region [61] and can be used as a proxy
for methylation levels in a Mendelian randomization
(MR) framework. Such sites, called methylation quanti-
tative trait loci (mQTLs), can influence the methylation
pattern across an extended genomic region [70] and can
be used as a proxy for methylation levels in a Mendelian
randomization (MR) framework [29].
To generate mQTLs, methylation data from a quality-
controlled subset of individuals (N, 5101) from the Gener-
ation Scotland: Scottish Family Health Study who had
undergone EPIC array DNA methylation profiling, de-
scribed previously [73], were used. Following measurement
of DNA methylation, normalization was performed using
the R package minfi [65, 74], producing M values [66, 75]
for downstream analysis. Briefly, linear mixed modelling
was used to remove potential effects from technical factors,
adjusting for both fixed and random effects. Fixed effects
included the top 50 principal components of control probe
intensities (explaining 99% of variation in control probe in-
tensities) [67, 76], clinic centre for blood draw appointment,
processing batch, year of clinic visit and sentrix position
(position of the sample on EPIC array slide). Random ef-
fects included blood draw appointment date and sentrix ID
(EPIC array slide). The model converged successfully for
712,595 sites. Outliers from this normalisation with
residualized-M-values more than five interquartile ranges
from the nearest quartile were removed [77].
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A GKFSC model [78, 79] was then fitted to derive
mQTLs from the normalised data, including 5 matrices
as random effects, and other covariates as fixed-effects.
The matrices were G (a genomic relationship matrix), K
(a kinship relationship matrix) [80, 81], F (an environ-
mental matrix representing nuclear-family-member rela-
tionships), S (an environmental matrix representing full-
sibling relationships) and C (an environmental matrix
representing couple relationships) [78, 79]. Covariates
(as fixed effects) included age, age2, gender, estimated
cell counts, season of clinic visit, appointment time of
the day and appointment day of the week. The model
successfully converged in 638,737 CpG sites.
Generation of instrumental variables for DMRs
Prior to MR analysis being conducted, we generated in-
strumental variables (IVs) proxying CpG sites identified
in analyses of both prognostic factors and survival (Sup-
plementary Figure 1). Where possible, we found DMRs
(P < 0.05) from our analyses for each prognostic factor
and looked for a corresponding DMR in our survival
analysis (model 1, unadjusted for prognostic factors).
CpG sites common to DMRs found this were retained.
Next, using the summary genetic data for mQTLs from
Generation Scotland, we extracted all mQTLs proxying any
CpG site per DMR grouping (MAF > 0.05; P < 5 × 10−8).
From this list, we generated instruments by LD pruning it-
eratively; first taking all mQTLs associated with the sentinel
CpG (defined as the CpG in each DMR with the lowest P
value) and clumping with an r2 of 0.01. We then took the
second most associated CpG in the DMR and extracted all
mQTLs associated with it which were not associated with
the previous CpG. The remaining mQTLs were then
clumped and combined with the mQTLs proxying the sen-
tinel CpG. This process was repeated for each CpG within
a DMR. Clumping and mQTL extraction were conducted
using R 3.4.1, with the TwoSampleMR R package [82].
In order to account for mQTL proxies influencing
methylation at multiple CpG sites, we conducted a meta-
analysis of mQTL-CpG effects. Per DMR, we used the
metafor R package [74, 83] to meta-analyse each mQTL
effect (beta) on methylation levels at each CpG using a re-
stricted maximum likelihood (REML) model, adjusting for
pairwise correlation between the CpG sites proxied by our
instrument. From this, we obtained an mQTL effect on
average methylation levels across the DMR.
mQTL associations with survival
The mQTLs identified above were then regressed against
survival in HN5000, using the SurvivalGWAS_SV pro-
gram to run Cox proportional-hazards survival analyses
with an additive dosage model for each of the selected
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Fig. 9 Smoothed-line plot showing minimum expected power for MR analyses using mQTLs to proxy gene regions. This figure denotes a lower
bound in expected power at different OR values rather than a definitive estimate. Sample size = 409; alpha = 0.05. Each plot denotes a different
proportion of variance explained, ranging from 5 to 50%
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SNPs [84]. Death from any cause was used as the failure
variable and time to death (or censoring) in days as the
time variable. Age at cancer diagnosis and sex were used
as covariables in the model. For each SNP, the log-
hazard ratio (and standard error) per minor allele was
reported.
Power calculation for Mendelian randomization analyses
Given the use of mQTL summary-level data rather than
individual-level data, we could not calculate the exact
variance explained of methylation across the multiple
DMR CpG sites we proxied. Therefore, we calculated
power for our analyses based on largest variance ex-
plained in methylation by a single mQTL for each region
analysed, in the knowledge that this would constitute a
minimum bound of the total variance explained when
combining multiple instruments. Accordingly, our power
calculations show an extremely conservative, minimum
estimate of power to conduct MR analyses. Power was
calculated using the mRnd power calculator (http://
cnsgenomics.com/shiny/mRnd/) using an alpha of 0.05
and sample size of 409 at different OR values, for a
range of r2 values (Fig. 9).
Mendelian randomization analyses
Following identification of shared methylation patterns
between prognostic factors and OPC survival, we
attempted to ascertain whether methylation was a true
causal intermediate, or simply just associated with both
prognostic factors and survival. To this end, we con-
ducted Mendelian randomization to appraise the causal
effect of DNA methylation on survival. To achieve this,
we conducted a two-sample MR analysis. In the first
sample, we used mQTL-DMR effect estimates (βGP)
from Generation Scotland, and in the second sample,
mQTL-survival estimates (βGD) from HN5000. For each
mQTL, we calculated the log HR per unit (β) increase in
DNA methylation at the DMR by the formula βGD/βGP
(Wald ratio). Standard errors were approximated by the
delta method. Where multiple mQTLs were available for
one DMR, these were combined in a fixed effects meta-
analysis after weighting each ratio estimate by the in-
verse variance of their associations with the outcome
(IVW approach). In order to account for correlation be-
tween mQTLs, we adjusted for genetic correlation using
LDMatrix [76, 85] to generate a genetic correlation
matrix (1000 Genomes reference standard) of mQTLs,
which was included as a covariate in our MR regression
analysis [86]. In addition to our main analysis detailed
above, we conducted multivariable MR Egger analysis as
an assessment of IV heterogeneity. We also conducted
sensitivity MR analyses by calculating the log HR per
unit increase in DNA methylation for the single most-
associated CpG with each DMR we analysed—as above,
Wald ratios were calculated for CpGs proxied by a single
mQTL, and IVW MR estimates were calculated when
multiple mQTLs were available to proxy a CpG.
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Additional file 1:Supplementary Figure 1. Heatmap showing
correlation between top CpG sites (P<1x10-7) from each prognostic
factor (alcohol consumption, HPV16 E6 seropositivity and smoking) and
survival EWAS (Model 1: ~3-year survival adjusted for age sex and
surrogate variables; Model 2: as Model 1, additionally adjusted for
HPV16E6 seropositivity, smoking status and alcohol intake). Strength of
association is shown by depth of colour; deeper red denotes a stronger
phenotypic association with a hypermethylated CpG and deeper cyan
denotes a stronger phenotypic association with a hypomethylated CpG.
Supplementary Figure 2. - Surrogate variables correlated at P<0.05
(Pearson's) with laser surgery in HN5000. Supplementary Figure 3. -
Surrogate variables correlated at P<0.05 (Pearson's) with surgery on an
OPC primary tumour in HN5000. Supplementary Figure 4. - Surrogate
variables correlated at P<0.05 (Pearson's) with neck resection surgery in
HN5000. Supplementary Figure 5. - Surrogate variables correlated at
P<0.05 (Pearson's) with teletherapy in HN5000. Supplementary Figure
6. - Surrogate variables correlated at P<0.05 (Pearson's) with
chemotherapy in HN5000. Supplementary Figure 7. - Surrogate
variables correlated at P<0.05 (Pearson's) with chemoradiotherapy in
HN5000. Supplementary Figure 8. - Surrogate variables correlated at
P<0.05 (Pearson's) with TNM stage in HN5000. Supplementary Figure
9. - Surrogate variables correlated at P<0.05 (Pearson's) with neutrophil-
to-lymphocyte ratio in HN5000.
Additional file 2: Supplementary Table 1. Genome-wide
differentially-methylated CpG sites associated with smoking status below
a multiple testing threshold of P < 2.4e-07. Results are adjusted for age,
sex, surrogate variables obtained by SVA, alcohol consumption and
HPV16E6 seropositivity. Supplementary Table 2. - Genome-wide
differentially-methylated CpG sites associated with alcohol consumption
below a multiple testing threshold of P < 2.4e-07. Results are adjusted for
age, sex, surrogate variables obtained by SVA, smoking status and
HPV16E6 seropositivity. Supplementary Table 3. - Genome-wide
differentially-methylated CpG sites associated with ~3-year survival below
a multiple testing threshold of P < 2.4e-07. Results are adjusted for age,
sex and surrogate variables obtained by SVA. Supplementary Table 4.
Genome-wide differentially-methylated CpG sites associated with ~3-year
survival below a multiple testing threshold of P < 2.4e-07. Results are ad-
justed for age, sex, surrogate variables obtained by SVA, smoking status,
alcohol consumption and HPV16E6 seropositivity. Supplementary Table
5. Genetic instrumental variables (IVs) used in Mendelian randomization
analyses to assess epigenetic mediation between prognostic factors and
~3-year survival. The final # SNPs denotes genetic IVs which both proxy a
CpG and where the same position is available in the genome-wide asso-
ciation study of 3-year survival survival. Supplementary Table 6.
Lookup of CpG sites in the MRCIEU EWAS Catalog across all EWAS ana-
lyses below a Bonferroni p-value threshold of 5.7e-08. Betas for all studies
reporting beta values are calculated as a weighted mean, weighted by
sample size. Supplementary Table 7. CpG sites (P<2.4e-7) associated
with ~3-year survival adjusted for age, sex and surrogate variables ob-
tained by SVA, compared against betas, standard errors and p-values at
the same sites when comorbidity and stage are included as additional
covariates in the EWAS model.
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